{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:11:16Z","timestamp":1789193476821,"version":"build-2803163510"},"reference-count":116,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting liver disease that affects millions of people around the world. It is best identified with a hepatic fat build-up that ultimately leads to inflammation and damage. The classification and nomenclature of NAFLD have long been a controversial topic, until 2020 when a group of international experts recommended substituting NAFLD with MAFLD (metabolic dysfunction-associated FLD). MAFLD was then terminologically complemented in 2023 by altering it to MASLD, i.e., metabolic dysfunction-associated steatotic liver disease (MASLD). Both the MAFLD and the MASLD terminologies comprise the metabolic element of the disorder, as they offer diagnostic benchmarks that are embedded in the metabolic risk factors that underlie the disease. MASLD (as a multisystemic disease) provides a comprehensive definition that includes a larger population of patients who are at risk of liver morbidity and mortality, as well as adverse cardiovascular and diabetes outcomes. MASLD highlights metabolic risks in lean or normal weight individuals, a factor that has not been accentuated or discussed in previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, and exercise therapies have not been extensively studied in MAFLD and MASLD. Nutrition plays a vital role in managing both conditions, where centralizing on a diet rich in whole vegetables, fruits, foods, healthy fats, lean proteins, and specific nutrients (e.g., omega-3 fatty acids and fibers) can improve insulin resistance and reduce inflammation. Thus, it is essential to understand the role of nutrition in managing these conditions and to work with patients to develop an individualized plan for optimal health. This review discusses prevention strategies for NAFLD\/MAFLD\/MASLD management, with particular attention to nutrition and lifestyle correction.<\/jats:p>","DOI":"10.3390\/nu16142220","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T11:30:55Z","timestamp":1720697455000},"page":"2220","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Management of Metabolic-Associated Fatty Liver Disease\/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-4491","authenticated-orcid":false,"given":"Mohammad","family":"Beygi","sequence":"first","affiliation":[{"name":"Department of Agricultural Biotechnology, College of Agriculture, Isfahan University of Technology (IUT), Isfahan 8415683111, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-2895","authenticated-orcid":false,"given":"Salma","family":"Ahi","sequence":"additional","affiliation":[{"name":"Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom 7414846199, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4060-328X","authenticated-orcid":false,"given":"Samaneh","family":"Zolghadri","sequence":"additional","affiliation":[{"name":"Department of Biology, Jahrom Branch, Islamic Azad University, Jahrom 7414785318, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6939-9898","authenticated-orcid":false,"given":"Agata","family":"Stanek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Angiology and Physical Medicine, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Batorego 15 St., 41-902 Bytom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0016-5085(80)90382-0","article-title":"Effect of pyridoxine deficiency on serum and liver transaminases in experimental liver injury in the rat","volume":"79","author":"Ludwig","year":"1980","journal-title":"Gastroenterology"},{"key":"ref_2","first-page":"283","article-title":"Nonalcoholic fatty liver disease","volume":"8","author":"Schaffner","year":"1986","journal-title":"Prog. Liver Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/apt.17165","article-title":"Extrahepatic morbidities and mortality of NAFLD: An umbrella review of meta-analyses","volume":"56","author":"Yi","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1002\/ctd2.9","article-title":"Back to the future: From the history of NAFLD to MAFLD to heterogeneity of disease","volume":"1","author":"Lonardo","year":"2021","journal-title":"Clin. Trans. Disc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"32","author":"Chan","year":"2023","journal-title":"JOMES"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.31083\/j.rcm2203082","article-title":"Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease","volume":"22","author":"Galiero","year":"2021","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Dalbeni, A., Beatrice, G., Cappelli, D., and Gomez-Peralta, F. (2022). Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. J. Clin. Med., 11.","DOI":"10.3390\/jcm11040968"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Micha\u0142owska, J., Miller-Kasprzak, E., and Bogda\u0144ski, P. (2021). Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. Nutrients, 13.","DOI":"10.3390\/nu13020351"},{"key":"ref_13","first-page":"691","article-title":"MASLD: A systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14740\/cr1459","article-title":"Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes","volume":"14","author":"Yanai","year":"2023","journal-title":"Cardiol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yanai, H., Hakoshima, M., Adachi, H., and Katsuyama, H. (2021). Multi-organ protective effects of sodium glucose cotransporter 2 inhibitors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094416"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wei, Q., Xu, X., Guo, L., Li, J., and Li, L. (2021). Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.635556"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e15347","DOI":"10.1016\/j.heliyon.2023.e15347","article-title":"Therapeutic potential of bioactive phytoconstituents found in fruits in the treatment of non-alcoholic fatty liver disease: A comprehensive review","volume":"9","author":"Pathak","year":"2023","journal-title":"Heliyon"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep4.2005","article-title":"Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study","volume":"6","author":"Akuta","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20420188231160394","DOI":"10.1177\/20420188231160394","article-title":"Non-pharmacological management options for MAFLD: A practical guide","volume":"14","author":"Stefano","year":"2023","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5114\/ceh.2020.102173","article-title":"SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: A systematic review","volume":"6","author":"Dwinata","year":"2020","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wong, C., Yaow, C.Y.L., Ng, C.H., Chin, Y.H., Low, Y.F., Lim, A.Y.L., Muthiah, M.D., and Khoo, C.M. (2021). Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in asian patients with type 2 diabetes: A meta-analysis. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.609135"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/hep4.2069","article-title":"Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus","volume":"6","author":"Arai","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3164\/jcbn.20-129","article-title":"Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: A prospective randomized study","volume":"68","author":"Tobita","year":"2021","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: The role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications\u2014A review","volume":"13","year":"2014","journal-title":"Nutr. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.2337\/diabetes.53.2007.S60","article-title":"Role of peroxisome proliferator-activated receptor-\u03b3 in the glucose-sensing apparatus of liver and \u03b2-cells","volume":"53","author":"Kim","year":"2004","journal-title":"Diabetes"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Perumpail, B.J., Cholankeril, R., Yoo, E.R., Kim, D., and Ahmed, A. (2017). An overview of dietary interventions and strategies to optimize the management of non-alcoholic fatty liver disease. Diseases, 5.","DOI":"10.3390\/diseases5040023"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Vidal-Cevallos, P., Sorroza-Mart\u00ednez, A.P., Ch\u00e1vez-Tapia, N.C., Uribe, M., Montalvo-Jav\u00e9, E.E., and Nu\u00f1o-L\u00e1mbarri, N. (2024). The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084397"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s12325-019-00898-6","article-title":"Pharmacological treatment for non-alcoholic fatty liver disease","volume":"36","author":"Francque","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Caturano, A., Galiero, R., Loffredo, G., Vetrano, E., Medicamento, G., Acierno, C., Rinaldi, L., Marrone, A., Salvatore, T., and Monda, M. (2023). Effects of a combination of empagliflozin plus metformin vs. metformin monotherapy on NAFLD progression in type 2 diabetes: The IMAGIN pilot study. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020322"},{"key":"ref_34","first-page":"e25495","article-title":"Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease","volume":"14","author":"Hassen","year":"2022","journal-title":"Cureus"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3945\/an.116.013730","article-title":"Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease","volume":"8","author":"Hsu","year":"2017","journal-title":"Adv. Nutr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.jhepr.2021.100253","article-title":"Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD","volume":"3","author":"Oh","year":"2021","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s40279-023-01918-w","article-title":"Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia","volume":"53","author":"Keating","year":"2023","journal-title":"Sports Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.2147\/DMSO.S304357","article-title":"Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease","volume":"14","author":"Machado","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_39","first-page":"242","article-title":"High-intensity interval training (HIIT) alleviated NAFLD feature via miR-122 induction in liver of high-fat high-fructose diet induced diabetic rats","volume":"126","author":"Delfan","year":"2018","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Staufer, K., and Stauber, R.E. (2023). Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?. Biomedicines, 11.","DOI":"10.3390\/biomedicines11082108"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11901-021-00563-z","article-title":"Dietary Interventions in Liver Diseases: Focus on MAFLD and Cirrhosis","volume":"20","author":"Lange","year":"2021","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Bagheri, S., Zolghadri, S., and Stanek, A. (2022). Beneficial Effects of Anti-Inflammatory Diet in Modulating Gut Microbiota and Controlling Obesity. Nutrients, 14.","DOI":"10.3390\/nu14193985"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Stanek, A., Bro\u017cyna-Tkaczyk, K., Zolghadri, S., Cholewka, A., and My\u015bli\u0144ski, W. (2022). The Role of Intermittent Energy Restriction Diet on Metabolic Profile and Weight Loss among Obese Adults. Nutrients, 14.","DOI":"10.3390\/nu14071509"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Stanek, A., Grygiel-G\u00f3rniak, B., Bro\u017cyna-Tkaczyk, K., My\u015bli\u0144ski, W., Cholewka, A., and Zolghadri, S. (2023). The Influence of Dietary Interventions on Arterial Stiffness in Overweight and Obese Subjects. Nutrients, 15.","DOI":"10.3390\/nu15061440"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ali, H., Shahzil, M., Moond, V., Shahzad, M., Thandavaram, A., Sehar, A., Waseem, H., Siddiqui, T., Dahiya, D.S., and Patel, P. (2024). Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice. J. Pers. Med., 14.","DOI":"10.3390\/jpm14010061"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice","volume":"63","author":"Marchesini","year":"2016","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajg.2010.488","article-title":"Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease","volume":"106","author":"Kistler","year":"2011","journal-title":"Off. J. Am. Coll. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.tem.2019.07.013","article-title":"Are lifestyle therapies effective for NAFLD treatment?","volume":"30","author":"Kurzbach","year":"2019","journal-title":"Trends Endocrinol. Metabol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Trenell","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zhang, C., and Yang, M. (2021). Current options and future directions for NAFLD and NASH treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147571"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/liv.14675","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than NAFLD","volume":"40","author":"Yamamura","year":"2020","journal-title":"Liver Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.dld.2021.05.014","article-title":"MAFLD vs NAFLD: Where are we?","volume":"53","author":"Mantovani","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40292-023-00558-5","article-title":"Metabolic dysfunction-associated fatty liver disease in newly diagnosed, treatment-naive hypertensive patients and its association with cardiorenal risk markers","volume":"30","author":"Theofilis","year":"2023","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/liv.15335","article-title":"One size does not fit all; practical, personal tailoring of the diet to NAFLD patients","volume":"42","author":"Grinshpan","year":"2022","journal-title":"Liver Int."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Chai, X.-N., Zhou, B.-Q., Ning, N., Pan, T., Xu, F., He, S.-H., Chen, N.-N., and Sun, M. (2023). Effects of lifestyle intervention on adults with metabolic associated fatty liver disease: A systematic review and meta-analysis. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1081096"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cld.1083","article-title":"\u201cYou are what You eat\u201d: The role of Dietary Macronutrients and Micronutrients in MaFlD","volume":"18","author":"Gillespie","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jama.2018.20579","article-title":"Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: A randomized clinical trial","volume":"321","author":"Schwimmer","year":"2019","journal-title":"JAMA"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wu, Y., Tan, Z., Zhen, J., Liu, C., Zhang, J., Liao, F., and Dong, W. (2023). Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: Findings from the NHANES. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-17223-0"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13059-018-1439-8","article-title":"Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption","volume":"19","author":"Sanders","year":"2018","journal-title":"Genome Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41575-021-00472-y","article-title":"Dietary carbohydrates and fats in nonalcoholic fatty liver disease","volume":"18","author":"Luukkonen","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Hydes, T., Alam, U., and Cuthbertson, D.J. (2021). The impact of macronutrient intake on non-alcoholic fatty liver disease (NAFLD): Too much fat, too much carbohydrate, or just too many calories?. Front. Nutr., 8.","DOI":"10.3389\/fnut.2021.640557"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s40200-023-01223-3","article-title":"Association of nonalcoholic fatty liver disease with the different types of dietary carbohydrates: A cross-sectional study","volume":"22","author":"Afsharfar","year":"2023","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s12276-021-00614-x","article-title":"The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease","volume":"53","author":"Park","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M22-1787","article-title":"Effect of calorie-unrestricted low-carbohydrate, high-fat diet versus high-carbohydrate, low-fat diet on type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial","volume":"176","author":"Hansen","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eprac.2021.12.010","article-title":"Fatty liver through the ages: Nonalcoholic steatohepatitis","volume":"28","author":"Younossi","year":"2022","journal-title":"Endocrinol. Pract."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"111847","DOI":"10.1016\/j.nut.2022.111847","article-title":"Effects of time-restricted feeding (16\/8) combined with a low-sugar diet on the management of non-alcoholic fatty liver disease: A randomized controlled trial","volume":"105","author":"Tinsley","year":"2023","journal-title":"Nutrition"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"155136","DOI":"10.1016\/j.metabol.2022.155136","article-title":"The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: A systematic review of randomised controlled trials","volume":"129","author":"Angelidi","year":"2022","journal-title":"Metabolism"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MCO.0000000000000762","article-title":"Beyond weight loss in nonalcoholic fatty liver disease: The role of carbohydrate restriction","volume":"24","author":"Risi","year":"2021","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s41430-022-01081-x","article-title":"Effects of a low free sugar diet on the management of nonalcoholic fatty liver disease: A randomized clinical trial","volume":"76","author":"Khodami","year":"2022","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"100256","DOI":"10.1016\/j.jhepr.2021.100256","article-title":"Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet\u2013a randomised controlled trial","volume":"3","author":"Holmer","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Dro\u017cd\u017c, K., Nabrdalik, K., Hajzler, W., Kwiendacz, H., Gumprecht, J., and Lip, G.Y. (2021). Metabolic-associated fatty liver disease (MAFLD), diabetes, and cardiovascular disease: Associations with fructose metabolism and gut microbiota. Nutrients, 14.","DOI":"10.3390\/nu14010103"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ciardullo, S., Vergani, M., and Perseghin, G. (2023). Nonalcoholic fatty liver disease in patients with type 2 diabetes: Screening, diagnosis, and treatment. J. Clin. Med., 12.","DOI":"10.3390\/jcm12175597"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.numecd.2022.12.010","article-title":"Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent","volume":"33","author":"Colosimo","year":"2023","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"100762","DOI":"10.1016\/j.aohep.2022.100762","article-title":"Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: A longitudinal cohort analysis","volume":"28","author":"Muthiah","year":"2023","journal-title":"Ann. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: An individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e003066","DOI":"10.1136\/bmjdrc-2022-003066","article-title":"Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus","volume":"11","author":"Chen","year":"2023","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: A clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: A nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"102063","DOI":"10.1016\/j.clinre.2022.102063","article-title":"Metabolic-associated fatty liver disease and the risk of cardiovascular disease","volume":"47","author":"Zhang","year":"2023","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"102292","DOI":"10.1016\/j.eclinm.2023.102292","article-title":"Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: A nationwide cohort study","volume":"65","author":"Moon","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: A randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Han, E., Lee, Y.-h., Lee, B.-W., Kang, E.S., and Cha, B.-S. (2020). Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: A 24-week randomized controlled trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010259"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"101675","DOI":"10.1016\/j.molmet.2023.101675","article-title":"A low-carbohydrate diet induces hepatic insulin resistance and metabolic associated fatty liver disease in mice","volume":"69","author":"Long","year":"2023","journal-title":"Mol. Metabol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1113\/JP275173","article-title":"Short-term feeding of a ketogenic diet induces more severe hepatic insulin resistance than an obesogenic high-fat diet","volume":"596","author":"Grandl","year":"2018","journal-title":"J. Physiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e03601-20","DOI":"10.1128\/mBio.03601-20","article-title":"Ketogenic diets induced glucose intolerance and lipid accumulation in mice with alterations in gut microbiota and metabolites","volume":"12","author":"Li","year":"2021","journal-title":"MBio"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41440-023-01179-0","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: Linear mixed-effects model analyses","volume":"46","author":"Mori","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11906-023-01242-8","article-title":"Mechanisms linking metabolic-associated fatty liver Disease (MAFLD) to Cardiovascular Disease","volume":"25","author":"Badmus","year":"2023","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Feng, Z., Zhao, F., Wang, Z., Tang, X., Xie, Y., and Qiu, L. (2024). The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations. BMC Gastroenterol., 24.","DOI":"10.1186\/s12876-024-03192-0"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1017\/S0007114523000399","article-title":"Impact of skeletal muscle mass evaluating methods on severity of metabolic associated fatty liver disease in non-elderly adults","volume":"130","author":"Zhou","year":"2023","journal-title":"Br. J. Nutr."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"191","DOI":"10.26599\/FSHW.2022.9250016","article-title":"Higher intakes of lysine, threonine and valine are inversely associated with non-alcoholic fatty liver disease risk: A community-based case-control study in the Chinese elderly","volume":"13","author":"Li","year":"2024","journal-title":"Food Sci. Hum. Wellness"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Yi, Y., Wang, C., He, J., and Chang, Y. (2023). Diet was less significant than physical activity in the prognosis of people with sarcopenia and metabolic dysfunction-associated fatty liver diseases: Analysis of the National Health and Nutrition Examination Survey III. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1101892"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/dom.13007","article-title":"Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial","volume":"19","author":"Khoo","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Ristic-Medic, D., Kovacic, M., Takic, M., Arsic, A., Petrovic, S., Paunovic, M., Jovicic, M., and Vucic, V. (2020). Calorie-restricted Mediterranean and low-fat diets affect fatty acid status in individuals with nonalcoholic fatty liver disease. Nutrients, 13.","DOI":"10.3390\/nu13010015"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"116811","DOI":"10.1016\/j.jep.2023.116811","article-title":"Erchen Decoction alleviates obesity-related hepatic steatosis via modulating gut microbiota-drived butyric acid contents and promoting fatty acid \u03b2-oxidation","volume":"317","author":"Zhang","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2200597","DOI":"10.1002\/mnfr.202200597","article-title":"Butyrate Attenuates Hepatic Steatosis Induced by a High-Fat and Fiber-Deficient Diet via the Hepatic GPR41\/43-CaMKII\/HDAC1-CREB Pathway","volume":"67","author":"Zheng","year":"2023","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Tian, A., Sun, Z., Zhang, M., Li, J., Pan, X., and Chen, P. (2023). Associations between dietary fatty acid patterns and non-alcoholic fatty liver disease in typical dietary population: A UK biobank study. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1117626"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-nutr-061021-030223","article-title":"Nonalcoholic fatty liver disease and omega-3 fatty acids: Mechanisms and clinical use","volume":"43","author":"Spooner","year":"2023","journal-title":"Annu. Rev. Nutr."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ajcnut.2023.11.013","article-title":"Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: The TANGO randomized controlled trial","volume":"119","author":"Chooi","year":"2023","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1111\/1751-7915.14293","article-title":"Akkermansia muciniphila alleviates high-fat-diet-related metabolic-associated fatty liver disease by modulating gut microbiota and bile acids","volume":"16","author":"Wu","year":"2023","journal-title":"Microb. Biotechnol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.30076","article-title":"Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: A randomized controlled trial","volume":"68","author":"Properzi","year":"2018","journal-title":"Hepatology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/CS20220572","article-title":"Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): Functional analysis of lipid metabolism pathways","volume":"136","author":"Badmus","year":"2022","journal-title":"Clin. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.advnut.2023.01.001","article-title":"Effect of dietary intervention, with or without cointerventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: A systematic review and Meta-Analysis","volume":"14","author":"Hall","year":"2023","journal-title":"Adv. Nutr."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/jhn.13069","article-title":"A Mediterranean and low-fat dietary intervention in non-alcoholic fatty liver disease patients: Exploring participant experience and perceptions about dietary change","volume":"36","author":"George","year":"2023","journal-title":"J. Hum. Nutr. Diet."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Gambardella, M.L., Scarlata, G.G.M., Lenci, I., Baiocchi, L., and Luzza, F. (2024). The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation. Medicina, 60.","DOI":"10.20944\/preprints202403.0587.v1"},{"key":"ref_108","first-page":"359","article-title":"Effects of Time-Restricted Hypocaloric Mediterranean Diet in Patients with Non-Alcoholic Fatty Liver Disease: Preliminary Data from the CHRONO-NAFLD Project","volume":"91","author":"Tsitsou","year":"2023","journal-title":"Proceedings"},{"key":"ref_109","first-page":"93","article-title":"Ten-Hour Intermittent Fasting Plus Mediterranean Diet Versus Mediterranean Diet Alone for Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"163","author":"Milgrom","year":"2024","journal-title":"Harefuah"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Cuesta, S., Lozano Garc\u00eda, N., Rodr\u00edguez-Fern\u00e1ndez, S., Fern\u00e1ndez-Avila, A.I., Bermejo, J., Fern\u00e1ndez-Avil\u00e9s, F., Mu\u00f1oz, P., Bouza, E., and Reigadas, E. (2024). Impact of the Mediterranean Diet on the Gut Microbiome of a Well-Defined Cohort of Healthy Individuals. Nutrients, 16.","DOI":"10.3390\/nu16060793"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.17308","article-title":"Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)","volume":"57","author":"Henry","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cgh.2021.12.043","article-title":"Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease","volume":"21","author":"Chun","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e0108","DOI":"10.1097\/HC9.0000000000000108","article-title":"American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease","volume":"7","author":"Stine","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/87559129.2017.1410172","article-title":"The powerful story against cardiovascular diseases: Dietary factors","volume":"34","author":"Kisioglu","year":"2018","journal-title":"Food Rev. Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1177\/2047487319843667","article-title":"Dietary components and risk of cardiovascular disease and all-cause mortality: A review of evidence from meta-analyses","volume":"26","author":"Kwok","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Castro-Barquero, S., Ruiz-Le\u00f3n, A.M., Sierra-P\u00e9rez, M., Estruch, R., and Casas, R. (2020). Dietary strategies for metabolic syndrome: A comprehensive review. Nutrients, 12.","DOI":"10.3390\/nu12102983"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/14\/2220\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:15:00Z","timestamp":1760109300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/14\/2220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":116,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["nu16142220"],"URL":"https:\/\/doi.org\/10.3390\/nu16142220","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}